I now have comprehensive information from multiple authoritative sources. Here is a full, well-organized answer:
Aspirin Loading in Stroke - What Guidelines Say
Acute Ischemic Stroke (not thrombolysed)
Aspirin 325 mg should be started within 24-48 hours of stroke onset in most patients with acute ischemic stroke. This dose has been shown to reduce the risk of early recurrent ischemic stroke, though it slightly increases hemorrhagic risk. This is a Class I, Level A recommendation (AHA/ASA).
- Goldman-Cecil Medicine: "In patients with a major stroke, aspirin 325 mg daily should be started within 24 hours after the onset of stroke."
- Barash Clinical Anesthesia: "Aspirin 325 mg has been shown to reduce the risk of early recurrent ischemic stroke. It is recommended within 24 to 48 hours of stroke onset in most patients."
This is based on the landmark IST and CAST trials showing a small but significant reduction in early recurrence.
If Thrombolysis (IV rtPA / Tenecteplase) was Given
Do NOT start aspirin within 24 hours of IV thrombolytic therapy - unless its benefit for a concurrent condition (e.g., ACS) clearly outweighs the bleeding risk. Aspirin is deferred to after the 24-hour post-lysis safety window.
High-Risk TIA or Minor (Nondisabling) Ischemic Stroke - Dual Antiplatelet Therapy (DAPT)
This is a major evidence-based recommendation. Two options are recognized:
| Regimen | Loading Dose | Duration | Evidence |
|---|
| Clopidogrel + Aspirin | Clopidogrel 600 mg on day 1, then 75 mg/day + Aspirin 50-325 mg/day | 21 days, then aspirin monotherapy | CHANCE trial (Chinese population) + POINT trial |
| Ticagrelor + Aspirin | Ticagrelor 180 mg loading, then 90 mg twice daily + Aspirin 300-325 mg day 1, then 75-100 mg/day | 30 days, then aspirin monotherapy | THALES trial |
Both DAPT regimens reduce recurrent stroke by ~30% compared to aspirin monotherapy, but increase major bleeding by ~40% (ticagrelor causes substantially more bleeding than clopidogrel).
- Harrison's 22E (2025): "The combination of clopidogrel or ticagrelor plus aspirin for 21-30 days followed by aspirin alone thereafter reduces the risk of stroke, MI, and vascular death by up to 30% compared with aspirin alone."
- Goldman-Cecil: "Long-term dual or triple antiplatelet therapy either increases bleeding without reducing the risk of recurrent stroke or reduces recurrent stroke without reducing long-term disability and is not recommended."
Long-Term Secondary Prevention (after the acute/DAPT phase)
Once the DAPT window closes, antiplatelet therapy for noncardioembolic stroke/TIA is:
- Aspirin 50-325 mg daily, OR
- Clopidogrel 75 mg daily, OR
- Aspirin 25 mg + extended-release dipyridamole 200 mg twice daily
Single-agent aspirin at maintenance doses is adequate. Routine long-term DAPT is not recommended due to bleeding risk without benefit in disability or death reduction.
Key Points to Remember
- Aspirin 325 mg is the loading/acute dose for non-thrombolysed ischemic stroke (within 24-48 h)
- Avoid aspirin for 24 h after IV thrombolysis
- DAPT (clopidogrel 600 mg load + aspirin, or ticagrelor 180 mg load + aspirin) is recommended for high-risk TIA and minor stroke - limited to 21-30 days only
- Long-term maintenance is single antiplatelet (aspirin 50-325 mg, clopidogrel, or aspirin-dipyridamole)
- Aspirin is not used in cardioembolic stroke - those patients require anticoagulation
Sources: Goldman-Cecil Medicine (International Edition); Harrison's Principles of Internal Medicine 22E (2025); Barash Clinical Anesthesia 9e; AHA/ASA 2013 Guideline (AAN PDF); AHA/ASA 2024 Primary Prevention of Stroke Guideline.